

- F1 Lymphoma patients with IgE deficiency have lower rates of remission compared with non-IgE deficient individuals: a pilot retrospective study
Morio et al
- F2 A Retrospective Case Series of Novel Unusual Phenotypes of Food Protein-Induced Enterocolitis
Harrison and Järvinen
- F3 When Water Becomes Harmful: A Prickling Mystery of Aquagenic Pruritus and its Psychosocial Burden
Singh
- F4 Quantifying Ocular Allergic Redness in a Controlled Allergen Challenge Environment Using a Smartphone-Based Imaging Platform
Abelson et al
- F5 First Reported Real World Clinical Anaphylaxis Treated with Neffy: A Case Series
Rosenblum et al
- F6 Long-Term Safety and Efficacy of Oral Deucricitibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
Funded by AllerVie
- F7 Impact of Body Mass Index on Response to Omalizumab in Patients with Chronic Spontaneous Urticaria
Funded by Genentech, Inc., a member of the Roche Group
- F8 Impact of Baseline Biomarkers on Response to Omalizumab in Patients with Chronic Spontaneous Urticaria
Funded by Genentech, Inc., a member of the Roche Group.
- F9 Efficacy and Safety of Long-term Epicutaneous Immunotherapy in Peanut-allergic Children Aged 4 Through 7 Years in the Phase 3 PEOPLE Trial
Funded by DBV Technologies
- F10 Correlating Changes in Skin Clearance/Clinical Reported Outcomes with Patient Reported Outcome Measures in Atopic Dermatitis
Funded by Eli Lilly and Company
- F11 Understanding the Impact of Long-Term Prophylaxis Switches for Patients With Hereditary Angioedema
Funded by Takeda Pharmaceuticals USA, Inc.
- F12 Lanadelumab's sustained effectiveness and safety for HAE long-term prophylaxis in patients from Puerto Rico: Final results from the EMPOWER Study
Funded by Takeda Development Center Americas, Inc
- F13 Matched-Adjusted Indirect Comparison Analysis Demonstrating Significantly Better Improvement in Patient-Reported Outcomes for Omalizumab Versus Dupilumab at 12 Weeks in Patients with Chronic Spontaneous Urticaria
Funded by Genentech, Inc., a member of the Roche Group.
- F14 Identification of Chronic Spontaneous Urticaria within Electronic Health Record using Machine Learning Algorithms
Funded by Genentech (Award # SL45290)
- F15 Long-Term Safety and Efficacy of Oral Deucricitibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension (OLE) Study
Funded by Funding: AllerVie
- F16 Design of a Phase 4, Prospective, Observational, Multicenter Registry to Assess Baseline Characteristics, Treatment Patterns, and Long-term Outcomes in Patients With Eosinophilic Esophagitis Initiating Dupilumab in Routine Clinical Practice
Funded by Sanofi and Regeneron Pharmaceuticals Inc.
- F17 Dupilumab Effectiveness Through Two Years in Patients with CRSwNP Treated in Real World Practice: Results from the Global AROMA Registry
Funded by Sanofi and Regeneron Pharmaceuticals Inc.
- F18 Ultra-sensitive testing identifies previously undetected KIT D816V mutations in patients with indolent systemic mastocytosis: Learnings from the PIONEER study of avapritinib
Funded by Blueprint Medicines Corporation.
- F19 Long-Term Effects of Avapritinib on Bone Health and Quality of Life in Patients With Indolent Systemic Mastocytosis: Analysis of the PIONEER Study
Funded by Blueprint Medicines Corporation.
- F20 Rationale and design of the Garadacimab REAL-world Treatment outcomes of effectiveness, safety and quality-of-life in patients with hereditary angioedema (GREAT) study
Funded by CSL Behring, LLC
- F21 Efficacy And Safety of Garadacimab Via Autoinjector/Pre-Filled Pen for Hereditary Angioedema Long-Term Prophylaxis – Interim Results From A Phase 3 Open-Label Extension Study
Funded by CSL Behring, LLC
- F22 Long-Term Efficacy Of Garadacimab For Hereditary Angioedema In Patients With Or Without Prior Exposure In A Phase 3 Open-Label Extension Study
Funded by CSL Behring, LLC
- F23 Baseline Characteristics Associated With Multicomponent Clinical Remission Following Dupilumab Treatment In Patients With Moderate-To-Severe Asthma
Funded by Sanofi and Regeneron Pharmaceuticals Inc

- F24 Dupilumab Treatment Significantly Reduces Age-associated Total IgE Levels in Young Children With Atopic Dermatitis
Funded by Sanofi and Regeneron Pharmaceuticals Inc.
- F25 Initiation of dupilumab led to reduced use of corticosteroids and antibiotics over 12 months in patients with chronic rhinosinusitis with nasal polyps treated in US real world practice
Funded by Sanofi and Regeneron Pharmaceuticals Inc.
- F26 Efficacy of tezepelumab in patients with severe, uncontrolled asthma grouped by median baseline serum IL-5 And IL-13 levels: Results from the phase 3 NAVIGATOR study
Funded by AstraZeneca and Amgen Inc.
- F27 Tezepelumab reduces and eliminates OCS use in OCS-dependent patients with severe asthma: Primary results from the phase 3b WAYFINDER study
Funded by AstraZeneca and Amgen Inc.
- F28 Improvements in asthma exacerbations, lung function, asthma control and health-related quality of life after tezepelumab initiation in patients with severe asthma: Interim results from the US phase 4 PASSAGE study
Funded by AstraZeneca and Amgen Inc.
- F29 Long-Term Safety and Disease Control of Ruxolitinib Cream in Children Aged 2 to 6 and 7 to 11 Years With Atopic Dermatitis: Results From the TRuE-AD3 Study
Funded by Incyte Corporation
- F30 Patient Preferences for Attributes of Prophylactic Treatment in Hereditary Angioedema: A Discrete-Choice Experiment
Funded by Ionis
- F31 Pooled REMIX-1/-2 Phase 3 Data: Early and Sustained Symptom Improvement With Remibrutinib in Chronic Spontaneous Urticaria
Funding by Novartis Pharma AG, Basel, Switzerland
- F32 No Clinically Meaningful Impact of Remibrutinib on Immunoglobulin Levels Or Infections In Chronic Spontaneous Urticaria
Funded by: Novartis Pharma AG, Basel, Switzerland
- F33 Dupilumab Safety and Efficacy in a Real – World Clinical Setting: The RAPID Asthma Registry
Funded by Sanofi and Regeneron Pharmaceuticals Inc.
- F34 Clinical Remission and Off-treatment Remission in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Preliminary Data from an Open-label Extension Study
Funded by Sanofi and Regeneron Pharmaceuticals Inc.
- F35 Treatment with Navenibart (STAR-0215) Reduces Attack Severity and Use of Rescue Medication in Patients with Hereditary Angioedema (HAE): Interim Results from the ALPHA-STAR Trial
Funding by Astria Therapeutics, Inc
- F36 Dupilumab Efficacy in Patients with Chronic Obstructive Pulmonary Disease (COPD) with Type 2 Inflammation across Baseline Eosinophil Counts
Funding by Sanofi and Regeneron Pharmaceuticals Inc
- F37 Health Care Resource Utilization (HCRU) of Patients With Chronic Spontaneous Urticaria (CSU) by Disease Control: Results From a United States (US) Claims Database Study
Funding by Novartis USA.
- F38 Angioedema in Chronic Spontaneous Urticaria (CSU) is Associated with Greater Health Care Resource Utilization (HCRU): Results From a United States (US) Claims Database Study
Funding by Novartis USA
- F39 Living with HAE with Normal C-1 Inhibitor: The Worry of When
Funding by Pharming Healthcare, Inc
- F40 Patient Insights Expand Understanding of APDS
Funding by Pharming Healthcare, Inc.
- F41 ARS-1 (epinephrine nasal spray) development, from pharmacokinetics and pharmacodynamics to real-world data in pediatric food allergy patients
Funded by ARS Pharmaceuticals
- F42 Use of Intranasal Epinephrine (Neffy) in a Patient Who Experienced Anaphylaxis to Subcutaneous Allergen Immunotherapy
Funded by ARS Pharmaceuticals
- F43 Pharmacokinetics by Epinephrine Products from Various Studies
Funded by: ARS Pharmaceuticals Inc.
- F44 Clinical Predictors of Asthma Remission: A Post Hoc Analysis of the ATLANTIS Study
Funding by Chiesi Farmaceutici S.p.A.
- F45 Stringent efficacy response of skin clearance and itch-free state with abrocitinib 100 mg versus dupilumab in patients with moderate-to-severe atopic dermatitis: a post hoc analysis of JADE COMPARE
Funding by Pfizer Inc.
- F46 Systemic JAK1 inhibition by abrocitinib in patients with moderate-to-severe atopic dermatitis is associated with decreased lesional skin Staphylococcus aureus abundance and increased microbial diversity
Funding by Pfizer Inc.